Masayuki Hata

Masayuki Hata

Auto-generated profile, based on publicly available information

Masayuki Hata

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Science
Verified
Journal Article
Closed access
FBFrançois Binet
François Binet
GCGaël Cagnone
Gaël Cagnone
SCSergio Crespo-Garcia
Sergio Crespo-Garcia
MHMasayuki Hata
Masayuki Hata
MNMathieu Neault
Mathieu Neault
PSPrzemyslaw Sapieha
Przemyslaw Sapieha
Remodeling senescent blood vessels: The retina is a thin layer of nervous tissue at the back of the eye that transforms light into neuronal signals. The retina is essential for vision and is supported by networks of blood vessels. In diabetic retinopathy, a common cause of vision loss, these microvessels degenerate and regrow in an aberrant manner. Such degeneration and regrowth can compromise the functioning of retinal nerve cells. Binet et al. observed that, after rapid proliferation, vascular endothelial cells in diseased blood vessels engaged molecular pathways linked to cellular senescence (see the Perspective by Podrez and Byzova). Senescent vascular units summoned an inflammatory response in which neutrophils extruded neutrophil extracellular traps onto diseased vessels to remodel them. This endogenous repair mechanism promoted the elimination of senescent blood vessels and could lead to beneficial vascular remodeling. Science , this issue p. eaay5356 ; see also p. 919

6 January 2023 in Science
Verified
Journal Article
Closed access
MHMasayuki Hata
Masayuki Hata
EAElisabeth M. M. A. Andriessen
Elisabeth M. M. A. Andriessen
MHMaki Hata
Maki Hata
RDRoberto Diaz-Marin
Roberto Diaz-Marin
FFFrédérik Fournier
Frédérik Fournier
PSPrzemyslaw Sapieha
Przemyslaw Sapieha
Age-related macular degeneration is a prevalent neuroinflammatory condition and a major cause of blindness driven by genetic and environmental factors such as obesity. In diseases of aging, modifiable factors can be compounded over the life span. We report that diet-induced obesity earlier in life triggers persistent reprogramming of the innate immune system, lasting long after normalization of metabolic abnormalities. Stearic acid, acting through Toll-like receptor 4 (TLR4), is sufficient to remodel chromatin landscapes and selectively enhance accessibility at binding sites for activator protein-1 (AP-1). Myeloid cells show less oxidative phosphorylation and shift to glycolysis, ultimately leading to proinflammatory cytokine transcription, aggravation of pathological retinal angiogenesis, and neuronal degeneration associated with loss of visual function. Thus, a past history of obesity reprograms mononuclear phagocytes and predisposes to neuroinflammation.

6 February 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SCSergio Crespo-Garcia
Sergio Crespo-Garcia
FFFrédérik Fournier
Frédérik Fournier
RDRoberto Diaz-Marin
Roberto Diaz-Marin
SKSharon Klier
Sharon Klier
DRDerek Ragusa
Derek Ragusa
PSPrzemyslaw Sapieha
Przemyslaw Sapieha

1 January 2017 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
MHMasayuki Hata
Masayuki Hata
KYKenji Yamashiro
Kenji Yamashiro
SOSotaro Ooto
Sotaro Ooto
Akio OishiAkio Oishi
Akio Oishi
HTHiroshi Tamura
Hiroshi Tamura
NYNagahisa Yoshimura
Nagahisa Yoshimura
Purpose: To investigate the difference in intraocular vascular endothelial growth factor (VEGF) concentration between pachychoroid neovasculopathy and neovascular age-related macular degeneration (nAMD) and its associations with responses to three monthly anti-VEGF injections as an initial treatment for the two conditions. Methods: This study included nine eyes with treatment-naïve pachychoroid neovasculopathy and 21 eyes with treatment-naïve nAMD. Before the initial intravitreal anti-VEGF injection, aqueous humor samples were collected and the concentration of VEGF was measured using enzyme-linked immunosorbent assay. The concentration was compared between the two conditions, and its associations with responses to anti-VEGF therapy were investigated. Results: The mean VEGF concentration in pachychoroid neovasculopathy was significantly lower than that in nAMD (63.4 ± 17.8 pg/ml and 89.8 ± 45.0 pg/ml, respectively; P = 0.035). The VEGF concentration was associated with the presence or absence of drusen (β = 0.503, P = 0.004). After anti-VEGF therapy, 6 (66.7%) of 9 eyes with pachychoroid neovasculopathy and 17 (81.0%) of 21 eyes with nAMD achieved dry macula (P = 0.640). Dry macula at 3 months and 12 months was significantly associated with a low VEGF concentration in pachychoroid neovasculopathy (P = 0.013 and P = 0.042, respectively), but not in nAMD (P = 0.108 and P = 0.219). Conclusions: The mean VEGF concentration in pachychoroid neovasculopathy was lower than that in nAMD, suggesting that the way in which VEGF is involved in angiogenesis may differ between pachychoroid neovasculopathy and nAMD.

30 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RTRyosuke Tamiya
Ryosuke Tamiya
MHMasayuki Hata
Masayuki Hata
ATAsako Tanaka
Asako Tanaka
MTMemiri Tsuchikawa
Memiri Tsuchikawa
NUNaoko Ueda-Arakawa
Naoko Ueda-Arakawa
ATAkitaka Tsujikawa
Akitaka Tsujikawa
Though vascular endothelial growth factors (VEGF) and other proangiogenic factors, such as angiopoietins (Ang), may be involved in the development of neovascular age-related macular degeneration (nvAMD), only drugs that inhibit the VEGF family are available for the treatment. The newly approved anti-VEGF drug faricimab, which also inhibits Ang-2, is expected to be effective in patients with AMD refractory to conventional anti-VEGF drugs. Therefore, we prospectively investigated the efficacy of faricimab in the treatment of aflibercept-refractory nvAMD. Patients with nvAMD who had been treated with aflibercept in the last year and required bimonthly injections were recruited. 25 eyes showed persistent exudative changes immediately before the faricimab injection (baseline). In these 25 eyes, switching to faricimab did not change visual acuity or central retinal thickness 2 months after the injection; however, 56% of eyes showed reduction or complete absorption of fluid. Notably, 25% of the eyes that showed dry macula at month 2 had no fluid recurrence for up to 4 months. These results indicate that faricimab could benefit some patients with aflibercept-refractory nvAMD.

1 September 2017 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
YKYu Kawashima
Yu Kawashima
MHMasayuki Hata
Masayuki Hata
Akio OishiAkio Oishi
Akio Oishi
SOSotaro Ooto
Sotaro Ooto
KYKenji Yamashiro
Kenji Yamashiro
ATAkitaka Tujikawa
Akitaka Tujikawa